All articles tagged with #intestinal blockage
A 9-year-old girl in Vietnam was hospitalized after a massive hairball caused a complete intestinal blockage, traced back to years of undetected hair eating linked to trichophagia. She underwent minimally invasive surgery and recovered well, highlighting the importance of early psychological intervention for such behaviors.
A 9-year-old girl in Vietnam was hospitalized with a life-threatening intestinal blockage caused by a nearly one-meter-long hairball resulting from years of hair-eating linked to trichophagia, which was successfully removed through minimally invasive surgery, highlighting the importance of early psychological intervention for such behaviors.
A Vietnam veteran in Oregon experienced a life-threatening blocked intestine after using the weight loss drug Ozempic, which is prescribed to manage type 2 diabetes. The drug, which mimics a hormone that makes someone feel full, can cause ileus, a condition where the intestines become blocked. In rare cases, this can lead to a rupture and spillage of intestinal contents, potentially triggering a fatal condition. The FDA has received reports linking 51 fatalities to weight-loss drugs containing semaglutide, the active ingredient in Ozempic. The drug's manufacturer, Novo Nordisk, claims to prioritize patient safety and works closely with the FDA to monitor the drug's safety profile.
The FDA has updated the label for Ozempic, an injectable diabetes drug, to include a warning about the potential side effect of intestinal blockage. The label change reflects reports of some users experiencing a condition called "ileus," which involves a blocking of the intestines. The FDA did not definitively establish a causal relationship between the drug's active ingredient, semaglutide, and the condition. This update follows a lawsuit from a woman who claims that Ozempic and its counterpart, Moujnaro, caused severe gastrointestinal side effects, including excessive vomiting and tooth loss. The drugmakers argue that these side effects are known and generally mild to moderate in severity. The label update may help protect the companies from legal action and inform patients about potential risks.
The US Food and Drug Administration (FDA) has updated the label of the diabetes drug Ozempic to acknowledge reports of blocked intestines in some users. Ozempic and its sister drug, Wegovy, have gained popularity for their ability to help people feel fuller longer. Drugmaker Novo Nordisk, the manufacturer of Ozempic and Wegovy, stated that patient safety is a priority and they are working closely with the FDA to monitor the safety profile of their medications. The labels of Wegovy and another diabetes drug, Mounjaro, also acknowledge reports of intestinal blockage. Some users have reported developing gastroparesis, but Novo Nordisk claims that gastrointestinal events are known side effects of GLP-1 agonists. A woman in Louisiana is suing Novo Nordisk and Eli Lilly over severe gastrointestinal events she claims were caused by using Ozempic and Mounjaro.
The FDA is updating the warning label for the diabetes and weight-loss drug Ozempic to include a potentially deadly side effect: intestinal blockage. The medication can cause a condition called ileus, where parts or all of the intestines become blocked, leading to tissue death and a risk of gastric juices leaking into the body. This complication, which has a fatality rate of up to one in ten, will be added to the already listed side effects of nausea, vomiting, diarrhea, and constipation. The FDA has received 33 reports of this condition out of 19,000 adverse reactions recorded, and Novo Nordisk, the manufacturer of Ozempic, maintains that the drug is safe and effective when used as directed.
The U.S. Food and Drug Administration (FDA) has updated the label for Ozempic, a type 2 diabetes drug commonly used for weight loss, to include a warning about the potential side effect of intestinal blockage. The FDA acknowledged increased reports of ileus, or the blockage of intestinal contents, associated with the drug's active ingredient, semaglutide. The labeling changes also apply to Wegovy, another weight loss drug made by the same manufacturer. This update comes after a lawsuit was filed against Novo Nordisk and Eli Lily, alleging that the drug makers failed to adequately warn patients about the risk of severe gastrointestinal problems associated with their medications.
Pope Francis, 86, is undergoing abdominal surgery to treat a "recurrent, painful and worsening" constriction of the intestine at Rome's Gemelli hospital. The Vatican said Francis would be put under general anesthesia for the procedure and would be hospitalized for several days. Francis had part of one lung removed when he was a young man and also suffers from sciatica nerve pain. He had 33 centimeters of his colon removed two years ago.